WST catalyst calendar

WEST PHARMACEUTICAL SERVICES INC

Upcoming catalysts
2
Cash runway
Cash generating
Cash & investments
$436M

WEST PHARMACEUTICAL SERVICES INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.

The next scheduled catalyst is Next quarterly earnings (projected) on October 22, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

WEST PHARMACEUTICAL SERVICES INC generates cash from operations, so a burn-based runway figure does not apply.

Upcoming catalysts

DateEventTypePhase
October 22, 2026 est. Next quarterly earnings (projected) Earnings —
March 15, 2030 Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients Trial Milestone Phase 2

Track WST alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open WST in the tracker

Recent history

DateEventTypePhase
July 23, 2026 Quarterly results filed (8-K) Earnings —
July 14, 2026 8-K filed: Material agreement Corporate —
June 1, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 15, 2026 RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms Trial Milestone Phase 2
May 11, 2026 8-K filed: Reg FD disclosure Filing —
April 23, 2026 Quarterly results filed (8-K) Earnings —
March 9, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
February 12, 2026 Quarterly results filed (8-K) Earnings —
October 23, 2025 Quarterly results filed (8-K) Earnings —
September 11, 2025 8-K filed: Leadership change Corporate —
July 24, 2025 Quarterly results filed (8-K) Earnings —
July 21, 2025 8-K filed: Leadership change Corporate —
May 12, 2025 8-K/A filed: Leadership change Corporate —
April 24, 2025 Quarterly results filed (8-K) Earnings —
April 24, 2025 8-K filed: Leadership change Corporate —
April 14, 2025 8-K filed: Leadership change Corporate —
March 27, 2025 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.